Evidence map›Paper›PMID 37321991›Full record

ArticleCell death discovery2023

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target.

Arwin Groenewoud, Jie Yin, Maria Chiara Gelmi, Samar Alsafadi, Fariba Nemati, Didier Decaudin, Sergio Roman-Roman, Helen Kalirai, Sarah E Coupland, Aart G Jochemsen and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Arwin GroenewoudInstitute of Biology, Leiden University, Leiden, The Netherlands. arwin.groenewoud@uk-erlangen.de.
Jie YinInstitute of Biology, Leiden University, Leiden, The Netherlands.
Maria Chiara GelmiDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Samar AlsafadiUveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, 75248 Paris, France.ORCID http://orcid.org/0000-0002-0060-1346
Fariba NematiLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France.
Didier DecaudinLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France.
Sergio Roman-RomanUveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, 75248 Paris, France.
Helen KaliraiLiverpool Ocular Oncology Research Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Sarah E CouplandLiverpool Ocular Oncology Research Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Aart G JochemsenDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-0570-7967
Martine J JagerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-2261-3820
Felix B EngelExperimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID http://orcid.org/0000-0003-2605-3429
B E Snaar-JagalskaInstitute of Biology, Leiden University, Leiden, The Netherlands. b.e.snaar-jagalska@biology.leidenuniv.nl.
Université Paris Sciences et Lettres · FRLeiden University · NLLeiden University Medical Center · NLUniversity of Liverpool · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 667787
6 · The paper itself

Abstract

Uveal melanoma (UM) has a high risk to progress to metastatic disease with a median survival of 3.9 months after metastases detection, as metastatic UM responds poorly to conventional and targeted chemotherapy and is largely refractory to immunotherapy. Here, we present a patient-derived zebrafish UM xenograft model mimicking metastatic UM. Cells isolated from Xmm66 spheroids derived from metastatic UM patient material were injected into 2 days-old zebrafish larvae resulting in micro-metastases in the liver and caudal hematopoietic tissue. Metastasis formation could be reduced by navitoclax and more efficiently by the combinations navitoclax/everolimus and flavopiridol/quisinostat. We obtained spheroid cultures from 14 metastatic and 10 primary UM tissues, which were used for xenografts with a success rate of 100%. Importantly, the ferroptosis-related genes GPX4 and SLC7A11 are negatively correlated with the survival of UM patients (TCGA: n = 80; Leiden University Medical Centre cohort: n = 64), ferroptosis susceptibility is correlated with loss of BAP1, one of the key prognosticators for metastatic UM, and ferroptosis induction greatly reduced metastasis formation in the UM xenograft model. Collectively, we have established a patient-derived animal model for metastatic UM and identified ferroptosis induction as a possible therapeutic strategy for the treatment of UM patients.

Identifiers

PMID37321991
PMCPMC10272172
OpenAlexW4380872810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.